
Genentech Highlights Breakthrough Phase III Results for Gazyva in Autoimmune Kidney Disease
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease Genentech, a member of the Roche Group announced today that the Phase III MAJESTY study in adults with primary membranous…











